Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor/Tezacaftor/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo‐Times

• Published in: Journal of magnetic resonance imaging Vol. 60; no. 1; pp. 116 - 124
• Main Authors: David, Mathieu, Benlala, Ilyes, Bui, Stephanie, Benkert, Thomas, Berger, Patrick, Laurent, François, Macey, Julie, Dournes, Gael
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.07.2024; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Aminophenols - therapeutic use; Benzodioxoles - therapeutic use; Bronchi - diagnostic imaging; Bronchiectasis; Bronchiectasis - diagnostic imaging; Bronchiectasis - drug therapy; CFTR; Computed tomography; Correlation coefficient; Correlation coefficients; Cystic fibrosis; Cystic Fibrosis - diagnostic imaging; Cystic Fibrosis - drug therapy; Drug Combinations; Evaluation; Female; Field strength; Health services; Humans; Indoles - therapeutic use; Longitudinal Studies; lung; Lung - diagnostic imaging; Lungs; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Male; Medical imaging; MRI; Patients; Population studies; Pulmonary functions; Pyrazoles; Pyridines - therapeutic use; Pyrroles - therapeutic use; Pyrrolidines; Quinolones - therapeutic use; Reproducibility; Respiratory function; Respiratory Function Tests; Retrospective Studies; Statistical analysis; Statistical tests; Subgroups; Treatment Outcome; Young Adult; lung; MRI; cystic fibrosis; CFTR

Background Lung magnetic resonance imaging (MRI) with ultrashort echo‐times (UTE‐MRI) allows high‐resolution and radiation‐free imaging of the lung structure in cystic fibrosis (CF). In addition, the combination of elexacaftor/tezacaftor/ivacaftor (ETI) has improved CF clinical outcomes such as need...